Beijing, China
Beijing Vigoo Biological Co. is building the New Vaccine National Engineering Research Center in the Beijing Economic-Technological Developement Area. The 22,749-sm project will cost RMB 200 million to build and is slated for completion in December of 2010. Construction began in late June of 2009. Supporting vaccine research and development for H1N1 influenza, hepatitis, and measles, the facility will include five pilot-scale production lines, laboratories, and support. Beijing Vigoo Biological Co. is comprised of China National Biotec Group, Beijing Tiantan Biological Products Corp, Beijing Biological Products Research Institute, and Chinese Disease Prevention and Control Center.
